News

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

May 30, 2024/

A pioneering once-a-day pill that regenerates nerve cell connections damaged by ALS has been FDA-approved for ongoing clinical trials. The drug is now being given to those with ALS and could be a watershed moment in the treatment of the fatal disease.

By Paul McClure


Click here to read the story.

Leave a Comment

You must be logged in to post a comment.

MATR Sponsor (view all)


Working to create a clean and balanced energy portfolio that will provide for a safe and reliable energy future. Learn more at http://www.NorthWesternEnergy.com/BrightFuture

MATR Supporters (view all)


Working closely with GFDA’s economic development team, HPF helps Montana businesses access the capital they need to expand, modernize, and strengthen local communities.

The Great Falls Development Alliance delivers aggressive, award-winning economic development support for business attraction, expansion, and retention.

We will bring the North Coast Hiawatha train route back to Southern Montana